{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:20Z","timestamp":1791902660672,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01568-6","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:50:56Z","timestamp":1782917456000},"page":"925-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deuruxolitinib: New Approval"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"1","key":"1568_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-025-00664-9","volume":"11","author":"B Ungar","year":"2025","unstructured":"Ungar B, Renert-Yuval Y, Dlova NC, et al. Alopecia areata. Nat Rev Dis Primers. 2025;11(1):77.","journal-title":"Nat Rev Dis Primers"},{"key":"1568_CR2","unstructured":"Sun Pharmaceutical Industries. U.S. FDA approves LEQSELVI(TM) (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata [media release]. 25 Jul 2024; http:\/\/www.sunpharma.com."},{"key":"1568_CR3","unstructured":"Sun Pharmaceutical Industries. LEQSELVI\u2122 (deuruxolitinib) tablets, for oral use: US Prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217900Orig1s000correctedlbl.pdf. Accessed 29 Apr 2026."},{"key":"1568_CR4","unstructured":"SUN Pharma UK Limited. Leqselvi 8 mg film-coated tablets: UK Summary of Product Characteristics. 2026. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/f95af329acb51af69ca13ab9238348ee2b7f89d5. Accessed 29 Apr 2026."},{"key":"1568_CR5","unstructured":"UK Medicines and Healthcare products Regulatory Agency (MHRA). MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults [media release]. 12 Mar 2026; https:\/\/www.gov.uk\/government\/news\/mhra-approves-deuruxolitinib-leqselvi-to-treat-severe-alopecia-areata-in-adults."},{"key":"1568_CR6","unstructured":"EMA. Applications for new human medicines under evaluation: March 2026. 2026. www.ema.europa.eu\/en\/documents\/report\/applications-new-human-medicines-under-evaluation-march-2026_en.xlsx. Accessed 29 Apr 2026."},{"key":"1568_CR7","unstructured":"Health Canada. Drug and health product submissions under review (SUR): new drug submissions under review. 2026. www.canada.ca\/en\/health-canada\/services\/drug-health-product-review-approval\/submissions-under-review\/new-drug-submissions-under-review.html#tbl. Accessed 29 Apr 2026."},{"key":"1568_CR8","unstructured":"Aclaris T. Aclaris Therapeutics announces patent license agreement with Sun Pharma for alopecia [media release]. 5 Dec 2023; http:\/\/www.aclaristx.com."},{"key":"1568_CR9","unstructured":"Concert Pharmaceuticals. Concert Pharmaceuticals announces notice of allowance for U.S. patent application related to CTP-543, lead candidate for treatment of alopecia areata [media release]. 22 Jan 2020; http:\/\/www.concertpharma.com."},{"key":"1568_CR10","unstructured":"Concert Pharmaceuticals. Concert Pharmaceuticals unveils CTP-543 for treatment of alopecia areata [media release]. 4 May 2016; http:\/\/www.concertpharma.com."},{"issue":"10","key":"1568_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"GS Timmins","year":"2014","unstructured":"Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24(10):1067\u201375.","journal-title":"Expert Opin Ther Pat"},{"issue":"4","key":"1568_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaad.2025.11.070","volume":"94","author":"A Tsianakas","year":"2026","unstructured":"Tsianakas A, Passeron T, Magnolo N, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026;94(4):1134\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1568_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1568_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14502","author":"B King","year":"2025","unstructured":"King B, Senna MM, Mesinkovska N, et al. Deuruxolitinib results in ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata: pooled long-term efficacy and safety data from open-label extension studies [abstract]. Australas J Dermatol. 2025. https:\/\/doi.org\/10.1111\/ajd.14502.","journal-title":"Australas J Dermatol"},{"key":"1568_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.223","author":"A Mostaghimi","year":"2025","unstructured":"Mostaghimi A, King B, Senna M, et al. Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials [abstract and presentation no. 62339]. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.223.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1568_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","volume":"87","author":"B King","year":"2022","unstructured":"King B, Mesinkovska N, Mirmirani P, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87(2):306\u201313.","journal-title":"J Am Acad Dermatol"},{"key":"1568_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1032","author":"B King","year":"2025","unstructured":"King B, Kempers S, Mesinkovska N, et al. Optimization of deuruxolitinib dosing in adult patients with alopecia areata: results from a randomized, parallel-group, multicenter, phase 2 trial [abstact and poster no. 62823]. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1032.","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01568-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01568-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01568-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:24Z","timestamp":1783821744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01568-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01568-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}